The United States is still getting rid of its chemical weapons
Representatives of Arab countries discuss Syria at the Arab League headquarters in Cairo, Egypt, on Tuesday, August 27. President al-Assad vowed to defend his country against any outside attack. “The threats of launching an aggression against Syria will increase its commitments,” and “Syria will defend itself against any aggression,” he said, according to Syrian state TV. Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria Suspected chemical attack in Syria HIDE CAPTION >> Photos: Suspected chemical attack in Syria The world’s attention turned to Syria’s chemical weapons stockpile after the United States and other countries accused Syria of using chemical weapons in an August 21 attack outside Damascus, a strike Washington says killed more than 1,400 people — including many women and children. Syria denies the accusation and says its own troops have faced poison gas attacks by rebel forces in the civil war that began in 2011. Last month, the U.N. Security Council later voted unanimously to require Syria to eliminate its arsenal of chemical weapons or face consequences. The U.N. team in Syria overseeing the destruction of Syria’s chemical weapons says the Assad regime is cooperating . Securing Syria’s chemical weapons won’t be easy It’s unclear how these weapons can be found, secured, and safely destroyed by next year in the middle of a protracted conflict, considering that it is expected to take the United States three years to destroy half of the chemical weapons that Syria is estimated to have — and that’s in a remote part of Kentucky with no civil war. Asked about that, the U.S. Department of Defense told CNN in a written statement that it’s “inaccurate to draw parallels between the U.S. chemical demilitarization program and the international cooperation that will be required to destroy the chemical stockpile in Syria.” Defected general says Syria will never give up chemical weapons CNN’s Elizabeth M. Nunez contributed to this report.
Why the United States and Canada should merge: Foreign Policy opinion
. . . And the Chinese have targeted our resources, along with everyone else’s,” Francis told Foreign Policy (FP) by phone from Canada. They’re “the wolves at the door,” Francis says; she frames the situation in terms of “prey and predator” in the book. “They’re gaming the system,” she told FP. “And I think they’re brilliant. I think they’re doing a great job feeding their population, frankly, and educating them, but we understand that they have an objective.” Their goal is to break into the biggest, wealthiest markets: the United States and the European Union. “Canada is . . . peripheral to the United States, as Turkey is [to the EU], and you’ll notice that the Chinese start to do business not in the EU, but in the periphery — Bulgaria, Turkey. They just landed a big contract for their avionics, their air-traffic controls. They’re building bridges; they’re building roads.” Canada, she says, “is a back-door entry into the main markets that they really want to get into but are somewhat prevented from.” For now, the United States and Canada are “nations in distress,” falling prey to dangerous investments while their military and diplomatic power slips relative to the rest of the world’s. “Without dramatic change,” she writes, “Canada will remain …
An ad campaign focuses on prescription painkiller addiction. Avi Israel’s son committed suicide in 2011 while addicted to pain pills. (Photo: Don Heupel for USA TODAY) Story Highlights Campaign raises awareness of painkiller abuse A New York man’s suicide spurred campaign CDC: Prescription drug abuse is a growing problem SHARE 486 CONNECT 109 TWEET 42 COMMENTEMAILMORE BUFFALO Michael Israel’s death of a self-inflicted gunshot wound in 2011 was a tragedy. The Buffalo 20-year-old had become despondent about his addiction to the powerful painkillers prescribed for his Crohn’s disease. “But the ultimate Greek tragedy is we allow this to happen every day,” his father, Avi Israel, said this week at the State University College at Buffalo, where he was part of the announcement of a western New York-wide public awareness campaign about the dangers of prescription drug abuse. “We want to stop the dying of our youth,” he said. The campaign, which grew out of a push by Avi Israel after his son’s death, involves billboards; television, print and online advertising; a website; and a 30-minute documentary produced by Buffalo public broadcaster WNED-TV that will air Oct. 22 on Buffalo-area TV stations. Avi Israel has been a frequent and vocal advocate since 2011 for tackling the growing problem of prescription drug abuse, including testimony in 2012 before the U.S. Senate Caucus on International Narcotics Control. His advocacy helped lead to New York lawmakers unanimously passing the Internet System for Tracking Over-Prescribing law, or “I-STOP,” which went into effect in August. The Centers for Disease Control and Prevention in 2012 called prescription drug abuse the fastest-growing drug problem in the United States. Between 1999 and 2009, the number of deaths nationwide from opioid painkillers such as hydrocodone and oxycodone nearly quadrupled, and such overdoses cause more deaths than cocaine and heroin combined, according to the Substance Abuse and Mental Health Services Administration. Avi Israel signs a pledge board for a campaign to raise awareness about prescription drug abuse Oct.
Teva Announces FDA Approval of Generic TOBI(R) in the United States
(NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI(R) (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI(R) had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013. About Teva Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012. Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, including our ability to develop, manufacture, market and sell biopharmaceutical products, competition for our innovative products, especially COPAXONE(R) (including competition from innovative orally-administered alternatives, as well as from potential purported generic equivalents), competition for our generic products (including from other pharmaceutical companies and as a result of increased governmental pricing pressures), competition for our specialty pharmaceutical businesses, our ability to achieve expected results through our specialty, including innovative, R&D efforts, the effectiveness of our patents and other protections for innovative products, decreasing opportunities to obtain U.S. market exclusivity for significant new generic products, our ability to identify, consummate and successfully integrate acquisitions, the effects of increased leverage as a result of recent acquisitions, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our potential exposure to product liability claims to the extent not covered by insurance, increased government scrutiny in both the U.S.
Actually, the United States Has Defaulted Before
The fourth big move was the day of the first default, when T-bill rates rose almost 0.6 percentage points (i.e., 60 basis points).Theres no indication this increase reversed in the days that followed (the vertical line on the chart is just a marker for the day of default). Indeed, using more sophisticated means, including comparing T-bill rates to interest on commercial paper, the authors conclude that default led to a persistent increase in T-bill rates and, therefore, higher borrowing costs for the federal government. The financial world has changed dramatically in the intervening decades. T-bill rates hover near zero compared to the 9-10 percent range of the late 1970s; that means a temporary delay in payments would be less costly for creditors. Treasurys IT systems are, one hopes, more reliable that 1970s vintage word processors. And one should take care not to make too much of a single data point. But its the only data point we have on a U.S. default. Not surprisingly it shows that even small, temporary default is a bad idea. Our leaders shouldnt come close to risking it. P.S. Some observers believe the United States also defaulted in 1933 when it abrogated the gold clause. The United States made its payments on time in dollars, but eliminated the option to take payment in gold.